Decision analysis for primary management of anemia in low/intermediate-1 risk myelodysplastic disorder (MDS).
| Treatment . | Serum EPO < 500mU/mL . | RBC, < 2 U/mo* . | Age, < 60 y . | Deletion 5q . |
|---|---|---|---|---|
| * RBC transfusion dependence for less than 6 mos is predictive of response to therapy. | ||||
| Abbrevations: ESA, erythropoiesis-stimulating agent; HMA, hypomethylating agents; IST, immunosuppressive therapy; sEPO, serum erythropoietin concentration; RBC, red blood cells; mos, months; yes, predictive for response; no, not predictive for response; NR, not relevant for prediction of response to therapy; | ||||
| ESA | Yes | Yes | NR | NR |
| ESA | Yes | No | NR | No |
| HMA | No | No | No | No |
| Lenalidomide | No | NR | NR | Yes |
| IST | No | Yes | Yes | No |
| Treatment . | Serum EPO < 500mU/mL . | RBC, < 2 U/mo* . | Age, < 60 y . | Deletion 5q . |
|---|---|---|---|---|
| * RBC transfusion dependence for less than 6 mos is predictive of response to therapy. | ||||
| Abbrevations: ESA, erythropoiesis-stimulating agent; HMA, hypomethylating agents; IST, immunosuppressive therapy; sEPO, serum erythropoietin concentration; RBC, red blood cells; mos, months; yes, predictive for response; no, not predictive for response; NR, not relevant for prediction of response to therapy; | ||||
| ESA | Yes | Yes | NR | NR |
| ESA | Yes | No | NR | No |
| HMA | No | No | No | No |
| Lenalidomide | No | NR | NR | Yes |
| IST | No | Yes | Yes | No |